Detalhe da pesquisa
1.
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
J Thorac Oncol
; 19(5): 732-748, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38154514
2.
Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome.
Blood Adv
; 7(24): 7445-7456, 2023 12 26.
Artigo
Inglês
| MEDLINE | ID: mdl-38091008
3.
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.
J Clin Invest
; 133(16)2023 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37384411